Betamethasone,Finasteride,Dutasteride,Cyproterone Acetate, Deflazacort,Flumethasone, Mometasone Furoate,Meprednisone,Diflorasone,8DM, DB11,17a-hydroxy progesterone,Temozolomide intermediate,Aspirin,Methylprednisolone intermediate,etc.
more >
Year of Establishment:
2002
Total Assets(USD):
Choose not to disclose
Total Number of Staff:
400 to 449
Main Competitive Advantages:
Other Competitive Advantages:
Patents and Copyrights:
Business Type:
Manufacturer
R&D capacity:
Annual Turnover(USD):
Choose not to disclose
Main Sales Markets:
North America,Central/South America,Western Europe,Eastern Europe,Asia,Middle East
Other Competitive Advantages:
Patents and Copyrights: